RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
ANNALS OF ONCOLOGY
Collezione ASL Cuneo 2

Items : 17

2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA) in Annals of Oncology

2024
ASL Cuneo 2
ASL Asti

Giannatempo P; Polymeropoulos A; Stellato M; Ambrosini P; Gusmaroli E; Cavalli C; Guadalupi V; Claps M; Raggi D; Rametta A; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;

1294P Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry in Annals of Oncology

2024
ASL Cuneo 2

Marinello A; Massa G; Rotow J; Bote De Cabo H; Monnet I; Guisier F; Duruisseaux M; Benitez Montanez JC; Raimbourg J; Costa J; Tagliamento M; Feng J; Di Federico A; Metro G; Citarella F; Tabbò F; Lindsay C; Iranzo Gomez P; Besse B; Aldea M;

1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis in Annals of Oncology

2024
ASL Cuneo 2
ASL Asti

Stellato M; Giannatempo P; Polymeropoulos A; Guadalupi V; Claps M; Ambrosini P; Raggi D; Rametta A; Cavalli C; Gusmaroli E; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;

1343P Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ?50% in Annals of Oncology

2024
ASL Cuneo 2

De Giglio A; Zullo L; Di Federico A; Cani M; Aldea M; Favorito V; Sadowska A; Hendriks LE; Gorría Puga T; Mezquita L; Tabbò F; Novello S; Ardizzoni A; Besse B; Gelsomino F;

2024
ASL Cuneo 2

De Giglio A; Zullo L; Di Federico A; Cani M; Aldea M; Favorito V; Sadowska A; Hendriks LE; Gorría Puga T; Mezquita L; Tabbò F; Novello S; Ardizzoni A; Besse B; Gelsomino F;

2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial in Annals of Oncology

2023
ASL Cuneo 2

Giannatempo P; Bottiglieri A; Guadalupi V; Marandino L; Raggi D; Stellato M; Rametta A; Baciarello G; Sepe P; Claps M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Cattaneo L; Verzoni E; Ortega C; Procopio G; Necchi A;

Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC) in Annals of Oncology

2023
ASL Cuneo 2

Paratore C; Audisio M; Bombaci S; Bungaro M; Dionisio R; Ferrari G; Gaudino E; Grassi L; Hotca A; Loddo C; Manuguerra G; Manzin E; Novello S; Numico G; Persano I; Sculli C; Sperone P; Valsecchi AA; Zucchini G; Vellani G;

1715P Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study in Annals of Oncology

2023
ASL Cuneo 2

Rossi A; Aimar G; Audisio M; Bungaro M; Caglio A; Di Liello R; Gamba T; Gargiulo P; Ghisoni E; Lombardi P; Marandino L; Mariniello A; Paratore C; Reale ML; Trastu F; Tuninetti V; Turco F; Fabi A; Perrone F; Di Maio M;

1337P Implementation of precision oncology in clinical practice: A nationwide survey in Italy in Annals of Oncology

2022
ASL Cuneo 2

Fasola G; Barducci MC; Pelizzari G; Aprile G; Grossi F; Pinto C; Daniele B; Giordano M; Ortega C; Silva RR; Tozzi V; Cavanna L;

1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) in Annals of Oncology

2022
ASL Cuneo 2

Stellato M; Buti S; Maruzzo M; Bersanelli M; Ermacora P; Maiorano BA; Prati V; De Giorgi UFF; Pierantoni F; Malgeri A; Mennitto A; Cavo A; Vitale MG; Santoni M; Carella C; Procopio G; Verzoni E; Santini D;

Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial in Annals of Oncology

2020
ASL Cuneo 2

Verzoni E; Claps M; Apollonio G; Guadalupi V; Montone R; Martinetti A; Sepe P; Mennitto A; Passalacqua R; Donini M; Atzori F; Ortega C; Morelli F; Bearz A; Chiuri VE; Mosca A; Milella M; Miceli R; Cognetti F; Procopio G;

Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network in Annals of Oncology

2020
ASL Biella
ASL Città di Torino
ASL Asti
AO Cuneo
ASL Cuneo 2
AOU Città della Salute di Torino

Fea E; Buttigliero C; Montagnani F; Comandone A; Gennari A; Tucci M; Chiappino I; Canton OD; Masini C; Sacco† C; Amoroso D; Sirotova Z; Ciccone G; Valcamonico F; Vanella P; Ortega C; Prati V; Bianchi S; Mosca A; Berruti A;

CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology

2017
AO Ordine Mauriziano
ASL Cuneo 2
AOU San Luigi di Orbassano

Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Cosmai L; Vignani F; Prati G; Scagliarini S; Berselli A; Pinto C; Baldari S; Annibale V; Lastoria S; Tucci M; Borsatti E; Monari F; Paganelli G; Verri E; Muto P; Panareo S; Mosca A; Storto G; et alii...

Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): Real world data from an Italian Expanded Access Program (EAP) in Annals of Oncology

2017
ASL Cuneo 2

Procopio G; Prisciandaro M; Iacovelli R; Mancini M; Fornarini G; Facchini G; Cartení G; Napolitano M; Sternberg CN; Caserta C; Bregni M; Massari F; Buti S; Biasco E; De Giorgi U; Zustovich F; Ratta R; Ortega C; Tortora G; Verzoni E;

Osteonecrosis of jaw (ONJ) after antiresorptive treatment (bisphosphonates, denosumab) of cancer-treatment induced bone loss (CTIBL): A negligible risk? in Annals of Oncology

2017
AOU Città della Salute di Torino
AOU Alessandria
ASL Cuneo 2

Gambino A; Cabras M; Fusco V; Bertetto O; De Martino I; Alessio M; Numico G; Cagnazzo C; Arizio F; Piccinni Leopardi M; Di Costanzo A; Crotto L; Matocci R; Lucarelli A; Grassi E; Saracino V; Fugazza C; Cinefra M; Marchetti F; Taverniti C; Stabile S; Monti M; Marchesi E;

The follow-up and lifestyle (FUCSAM project). Oncology network of piemonte and Valle D'Aosta (ROPVdA): Preliminary data in Annals of Oncology

2015
ASL Alessandria
AOU Città della Salute di Torino
ASL Cuneo 2

Bertetto O; Pacquola MG; Romaniello I; Castiglione F; Bellingeri P; De Piccoli N; Fedi A; Gattino S; Finocchiaro C; Mistrangelo M; Mano MP; Monagheddu C; Viale M; Ciccone G; Senore C; Giordano L;

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer in Annals of Oncology

2014
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 2

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A; Rulli E; Cropalato Di Tullio M; et alii...